PT - JOURNAL ARTICLE AU - Yan, Cunye AU - Chen, Yue AU - Sun, Chenyu AU - Ahmed, Mubashir Ayaz AU - Bhan, Chandur AU - Cheng, Ce AU - Hu, Lei AU - Guo, Zhichun AU - Yang, Hongru AU - Cao, Chenyu AU - Ji, Ziwei AU - Yan, Yue AU - Zuo, Yijing AU - Sun, Yiceng AU - Li, Yao AU - Zhou, Qin TI - Will Proton Pump Inhibitors Lead to a Higher Risk of COVID-19 Infection and Progression to Severe Disease? A Meta-analysis AID - 10.1101/2020.12.25.20248860 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.25.20248860 4099 - http://medrxiv.org/content/early/2020/12/30/2020.12.25.20248860.short 4100 - http://medrxiv.org/content/early/2020/12/30/2020.12.25.20248860.full AB - Background Previous researches on the association between proton pump inhibitors (PPIs) use and the treatment and prevention of COVID-19 have generated inconsistent findings. Therefore, this Meta-analysis was conducted to clarify the outcome in patients who take PPIs.Methods We carried out a systematic search to identify potential studies until November 2020. Heterogeneity was assessed using the I-squared statistic. Odds ratios (ORs) with its 95% confidence intervals (CIs) were calculated by fixed-effects or random-effects models according to the heterogeneity. Sensitivity analyses and tests for publication bias were also performed.Results Eight articles with more than 268,683 subjects were included. PPI use was not associated with increased or decreased risk of COVID-19 infection (OR:3.16, 95%CI = 0.74-13.43, P=0.12) or mortality risk of COVID-19 patients (OR=1.91, 95% CI=0.86-4.24, P=0.11). While it can add risk of severe disease (OR=1.54, 95% CI=1.20-1.99, P<0.001;) and secondary infection (OR=4.33, 95% CI=2.57-7.29). No publication bias was detected.Conclusions PPI use is not associated with increased risk infection and may not change the mortality risk of COVID-19, but appeared to be associated with increased risk of progression to severe disease and secondary infection. However, more original studies to further clarify the relationship between PPI and COVID-19 are still urgently needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding support for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a meta-analysis and ethics committee approvals are not applicable here.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a meta-analysis, and all data are extracted from original studies that can retrieved from online data bases and other resourses.